Peregrine Pharmaceuticals General Counsel Mark Ziebell's 2020 pay jumps 124% to $1.1M
Peregrine Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: August 27, 2020
Peregrine Pharmaceuticals reported fiscal year 2020 executive compensation information on August 27, 2020.
In 2020, four executives at Peregrine Pharmaceuticals received on average a compensation package of $846K, a 51% increase compared to previous year.
Average pay of disclosed executives at Peregrine Pharmaceuticals
Mark R. Ziebell, General Counsel, received $1.1M in total, which increased by 124% compared to 2019. 35% of Ziebell's compensation, or $378K, was in option awards. Ziebell also received $34K in non-equity incentive plan, $372K in salary, $255K in stock awards, as well as $46K in other compensation.
For fiscal year 2020, the median employee pay was $83,115 at Peregrine Pharmaceuticals. Therefore, the ratio of Mark R. Ziebell's pay to the median employee pay was 13 to one.
Daniel R. Hart, Chief Financial Officer, received a compensation package of $842K, which increased by 7% compared to previous year. 47% of the compensation package, or $396K, was in salary.
Richard B. Hancock, Chief Executive Officer, earned $774K in 2020.
Roger J. Lias, Chief Executive Officer, received $681K in 2020, which decreases by 23% compared to 2019.
Peregrine Pharmaceuticals' fiscal year ends on April 30.
Related executives
You may also like
Source: SEC filing on August 27, 2020.